Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Current Portion of Long-Term Debt
Sonoma Pharmaceuticals Inc
Current Portion of Long-Term Debt Peer Comparison
Competitive Current Portion of Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Current Portion of Long-Term Debt
$2.3B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-5%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Current Portion of Long-Term Debt
$2.9B
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
26%
|
|
Pfizer Inc
NYSE:PFE
|
Current Portion of Long-Term Debt
$1B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-20%
|
|
Merck & Co Inc
NYSE:MRK
|
Current Portion of Long-Term Debt
$3.1B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-10%
|
|
Eli Lilly and Co
NYSE:LLY
|
Current Portion of Long-Term Debt
$1.7B
|
CAGR 3-Years
591%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
68%
|